Additionally, M2-type TAMs show a decrease in the production of cytokines and chemokines, while there is a trend toward an increase in the number of CD8+ and CD4+ T cells, which have antitumor effects.249 These phenomena suggest that CCR2 antagonists are able to reduce the infiltration of intratumorally M2-type TAMs and increase the number of CD8+ T cells and CD8+ TILs with tumor-killing effects in the microenvironment of peripheral blood. The gene discussed is CD8A; the disease is neoplasm.